TrialHaematologica2014

Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.

Santiago Montes-Moreno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.